A lonely band of five senators sat on the ‘Noes’ side of the Senate chamber during the government’s pre-Easter legislative blitz.

When Federal Parliament moved to amend the National Health Act and broaden the legal definition of ‘vaccine’, only five senators voted against it. Senators Antic, Roberts, Babet, Bell and Whitten stood opposed, while 39 senators waved it through.

To most Australians, the bill looked technical, obscure and largely unremarkable. A minor legislative adjustment buried in the machinery of Parliament.

It was anything but.

Hidden inside that minor amendment is a significant shift in Australia’s immunisation framework, one that paves the way for an entirely new class of pharmaceutical products to be funded, promoted, and normalised under the trusted banner of the National Immunisation Program.

The key change is deceptively simple. Where the law once defined vaccines in the traditional sense – products designed to stimulate the body’s own immune response – the new wording broadens the definition to include products that confer ‘passive immunity’. This wording change matters enormously.

Passive immunity products do not train the immune system to recognise and remember infection. They do not create immune memory. Instead, they provide pre-formed laboratory antibodies – temporary pharmaceutical protection that wanes over time – meaning repeated doses may be required. Sound familiar?

This is the realm of monoclonal antibodies.

With one legislative stroke, monoclonal antibody products now sit beneath the same administrative umbrella as conventional vaccines. This is Australia’s second vaccine definition change in recent years, following the TGA’s belated webpage update to include mRNA products in 2023.

In an attempt to ensure strict safety oversight of these products, Senator Malcolm Roberts moved an amendment requiring that any vaccine product accepted into this framework be ‘tested against an inert saline placebo to international standard’.

Astonishingly, this was voted down 43 to 5 begging the question, if this was merely harmless statutory language change, why was a modest safeguard rejected so decisively?

More importantly, why alter the vaccine definition now?

The answer lies in what has been unfolding behind the scenes in recent years.

In Sanofi’s own May 2025 Public Summary Document to the Pharmaceutical Benefits Advisory Committee for Beyfortus (nirsevimab) – its long-acting monoclonal antibody for Respiratory Syncytial Virus (RSV) – the company stated that the National Immunisation Program was ‘the most appropriate framework’ for a whole-of-population RSV program and explicitly acknowledged that the current legislative framework underpinning the NIP may not support the inclusion of passive immunisation strategies like nirsevimab.

That is a remarkable admission.

Before Parliament broadened the vaccine definition, the manufacturer seeking nationwide taxpayer-funded rollout of its monoclonal antibody product had already identified the legislative framework as a barrier.

The definitional change therefore does not sit in a vacuum. It sits directly alongside an active pharmaceutical push to secure NIP compatibility for passive immunisation products.

And first in line is Beyfortus.

Beyfortus is not a vaccine in the traditional sense. It is a monoclonal antibody injection designed to supply pre-formed RSV antibodies to newborns and young infants entering their first RSV season. Several Australian states have already begun funding broad access programs, while clinicians and industry advocates continue pressing for national inclusion.

But inclusion on the National Immunisation Program offers more than public subsidy. It offers public legitimacy.

In pharmaceutical-sponsored commentary discussing RSV rollout, infectious diseases physician Professor Paul Griffin stated that NIP inclusion would ‘send a clear message of trust and contribute to a high uptake’, adding that when a product does not make it onto the funded national schedule, people often begin to question why.

That observation is telling.

To place a product under the vaccine banner and inside the NIP is not simply to fund it. It essentially wraps it in the accumulated authority of public health endorsement, signalling safety, normality, and necessity.

A monoclonal antibody presented as a ‘vaccine’ will be received very differently from a monoclonal antibody presented as a novel pharmaceutical intervention.

That distinction matters because Beyfortus arrives carrying unanswered questions.

RSV is real, common, and highly contagious. By the age of two, around 90 per cent of children will have encountered it. Severe illness is concentrated in infants under six months, and a small percentage will require hospitalisation.

But death in otherwise healthy infants remains rare.

That matters because population-wide pharmaceutical interventions should not be judged simply on whether a disease exists, but on whether the proposed intervention clearly outweighs the disease burden, risk profile and available alternatives.

And this is where the public discussion becomes far less comfortable.

Questions have been raised regarding the safety profile of RSV monoclonal antibody products, with one expert stating that clinical trial data show more infant deaths in treatment groups than in controls across multiple studies. Further concern emerged in post-marketing surveillance, where pooled analysis indicated a markedly higher rate of seizures shortly after administration in infants receiving nirsevimab.

Professor Robert Clancy, one of Australia’s senior immunologists, agrees the products are not without risks. Issuing an unusually direct warning, he told me:

‘There is nothing wrong with the current vaccine definition. A vaccine is “part/whole of a pathogen (inactivated or attenuated) that acting as an antigen stimulates the same immunity as does the infection, without damage associated with infection”. It’s important to note that mRNA is NOT a vaccine, but genetic therapy acting on the cell’s genetic machinery to manufacture an antigen. Furthermore, changing the definition to allow use of monoclonals for RSV etc is simply ridiculous. History points to the danger of promoting RSV infection, rather than preventing it.’

This is not an anti-medicine argument.

It is an argument for proportion, transparency and caution – particularly when the recipients are healthy newborns.

There is also the issue almost absent from official enthusiasm: natural protection.

A major international review involving 16,787 infants across 31 countries found that exclusive breastfeeding beyond four to six months significantly reduced RSV hospitalisation, oxygen requirement, ICU admission and disease severity.

That evidence does not fit neatly into a pharmaceutical rollout, but it does raise an uncomfortable question:

Why is legislative energy being directed toward redefining vaccines to accommodate monoclonal injections, while comparatively little public urgency is directed toward strengthening breastfeeding – one of the simplest and safest infant protection already available?

Breast might be best, but it offers no patent, no profit, and no pharmaceutical sponsor.

In my opinion, therein lies much of the answer.

Dr Julie Sladden is a (retired) doctor. If you’d like to support her caffeine-inspired writing, you can shout her a coffee here.